Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease

PURPOSE: Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary condition characterized by massive kidney enlargement and developmental liver defects. Potential consequences during childhood include the need for kidney replacement therapy (KRT). We report the design of 2 ongoing clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Mekahli, Djalila, Liebau, Max C., Cadnapaphornchai, Melissa A., Goldstein, Stuart L., Greenbaum, Larry A., Litwin, Mieczyslaw, Seeman, Tomas, Schaefer, Franz, Guay-Woodford, Lisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926647/
https://www.ncbi.nlm.nih.gov/pubmed/36782137
http://dx.doi.org/10.1186/s12882-023-03072-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926647/
https://www.ncbi.nlm.nih.gov/pubmed/36782137
http://dx.doi.org/10.1186/s12882-023-03072-x

Ejemplares similares